Ovariectomy Stimulates and Bisphosphonates Inhibit Intracortical Remodeling in the Mouse Mandible

Overview

Journal Orthod Craniofac Res

Specialty Dentistry

Date 2010 Nov 3

PMID 21040464

Citations 18

Authors

D J Kubek

D B Burr

M R Allen

Affiliations

Soon will be listed here.

Abstract

Objective: The pathophysiology of osteonecrosis of the jaw (ONJ) is thought to be linked to suppression of intracortical remodeling. The aim of this study was to determine whether mice, which normally do not undergo appreciable amounts of intracortical remodeling, could be stimulated by ovariectomy to remodel within the cortex of the mandible and if bisphosphonates (BPs) would suppress this intracortical remodeling.

Material And Methods: Skeletally mature female C3H mice were either ovariectomized (OVX) or SHAM operated and treated with two intravenous doses of zoledronic acid (ZOL, 0.06 mg/kg body weight) or vehicle (VEH). This ZOL dose corresponds to the dose given to patients with cancer on a mg/kg basis, adjusted for body weight. Calcein was administered prior to sacrifice to label active formation sites. Dynamic histomorphometry of the mandible and femur was performed.

Results: Vehicle-treated OVX animals had significantly higher (eightfold) intracortical remodeling of the alveolar portion of the mandible compared to sham--this was significantly suppressed by ZOL treatment. At all skeletal sites, overall bone formation rate was lower with ZOL treatment compared to the corresponding VEH group.

Conclusions: Under normal conditions, the level of intracortical remodeling in the mouse mandible is minimal but in C3H mice it can be stimulated to appreciable levels with ovariectomy. Based on this, if the suppression of intracortical remodeling is found to be part of the pathophysiology of ONJ, the ovariectomized C3H mouse could serve as a useful tool for studying this condition.

Citing Articles

Preclinical Rodent Models for Human Bone Disease, Including a Focus on Cortical Bone.

Koh N, Miszkiewicz J, Fac M, Wee N, Sims N Endocr Rev. 2024; 45(4):493-520.

PMID: 38315213 PMC: 11244217. DOI: 10.1210/endrev/bnae004.

Pathophysiology of Medication-Related Osteonecrosis of the Jaw-A Minireview.

Tetradis S, Allen M, Ruggiero S JBMR Plus. 2023; 7(8):e10785.

PMID: 37614299 PMC: 10443081. DOI: 10.1002/jbm4.10785.

Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Aguirre J, Castillo E, Kimmel D Bone. 2021; 153:116184.

PMID: 34520898 PMC: 8743993. DOI: 10.1016/j.bone.2021.116184.

The effect of high concentration of zoledronic acid on tooth induced movement and its repercussion on root, periodontal ligament and alveolar bone tissues in rats.

de Sousa F, de Sousa Ferreira V, Martins C, Dantas H, de Sousa F, Girao-Carmona V Sci Rep. 2021; 11(1):7672.

PMID: 33828221 PMC: 8027035. DOI: 10.1038/s41598-021-87375-9.

Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (6), assessment of mandibular metabolism due to long-term administration of an anti-resorptive agent by bone scintigraphy (secondary publication).

Ohbayashi Y, Nakai F, Iwasaki A, Ogawa T, Yamamoto Y, Nishiyama Y Jpn Dent Sci Rev. 2019; 55(1):51-57.

PMID: 30815045 PMC: 6378901. DOI: 10.1016/j.jdsr.2018.11.002.

References

Frost H . Micropetrosis. J Bone Joint Surg Am. 1960; 42-A:144-50. View

Huja S, Fernandez S, Phillips C, Li Y . Zoledronic acid decreases bone formation without causing osteocyte death in mice. Arch Oral Biol. 2009; 54(9):851-6. DOI: 10.1016/j.archoralbio.2009.06.002. View

Gotcher J, Jee W . The progress of the periodontal syndrome in the rice cat. II. The effects of a diphosphonate on the periodontium. J Periodontal Res. 1981; 16(4):441-55. DOI: 10.1111/j.1600-0765.1981.tb00995.x. View

Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y . Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res. 2010; 25(7):1668-79. PMC: 3154005. DOI: 10.1002/jbmr.37. View

Parfitt A, Drezner M, Glorieux F, Kanis J, MALLUCHE H, Meunier P . Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2(6):595-610. DOI: 10.1002/jbmr.5650020617. View

Smith S, Recker R, Hannan M, Muller R, Bauss F . Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone. 2003; 32(1):45-55. DOI: 10.1016/s8756-3282(02)00923-7. View

Borah B, Dufresne T, Nurre J, Phipps R, Chmielewski P, Wagner L . Risedronate reduces intracortical porosity in women with osteoporosis. J Bone Miner Res. 2009; 25(1):41-7. DOI: 10.1359/jbmr.090711. View

Allen M, Iwata K, Phipps R, Burr D . Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. 2006; 39(4):872-9. DOI: 10.1016/j.bone.2006.04.028. View

Melsen B . Tissue reaction to orthodontic tooth movement--a new paradigm. Eur J Orthod. 2002; 23(6):671-81. DOI: 10.1093/ejo/23.6.671. View

10.

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

11.

Li C, Schaffler M, Wolde-Semait H, Hernandez C, Jepsen K . Genetic background influences cortical bone response to ovariectomy. J Bone Miner Res. 2005; 20(12):2150-8. DOI: 10.1359/JBMR.050819. View

12.

Biasotto M, Chiandussi S, Zacchigna S, Moimas S, Dore F, Pozzato G . A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw. J Oral Pathol Med. 2010; 39(5):390-6. DOI: 10.1111/j.1600-0714.2009.00878.x. View

13.

Allen M, Burr D . Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 2008; 66(5):987-94. PMC: 2464292. DOI: 10.1016/j.joms.2008.01.038. View

14.

Jowsey J . Studies of Haversian systems in man and some animals. J Anat. 1966; 100(Pt 4):857-64. PMC: 1270831. View

15.

Baumann B, Wronski T . Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone. 1995; 16(2):247-53. DOI: 10.1016/8756-3282(94)00036-y. View

16.

Marx R, Sawatari Y, Fortin M, Broumand V . Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63(11):1567-75. DOI: 10.1016/j.joms.2005.07.010. View

17.

Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S . Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab. 2009; 27(6):663-72. DOI: 10.1007/s00774-009-0090-6. View

18.

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

19.

Feher A, Koivunemi A, Koivunemi M, Fuchs R, Burr D, Phipps R . Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. Bone. 2009; 46(1):203-7. DOI: 10.1016/j.bone.2009.10.023. View

20.

Allen M, Kubek D, Burr D, Ruggiero S, Chu T . Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs. Osteoporos Int. 2010; 22(2):693-702. PMC: 2999646. DOI: 10.1007/s00198-010-1268-4. View